RPL37P25

Across TCGA pan-cancer cohorts, RPL37P25 RNA is linked to patient survival in 8 of 34 cancer types, making it the most broadly survival-associated RPL37P25 data layer.

The strongest signal is observed in adrenocortical carcinoma (ACC), where higher RPL37P25 RNA is associated with worse disease-free survival. In most high-consensus cancer types, elevated RPL37P25 expression acts as an unfavorable survival marker, although some lineages such as SKCM and BLCA show a favorable association.

ACC, SKCM, and COAD are the cancer types where RPL37P25 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
ACC	DFS	Tertile	IV	0.048	0.435	<.001	30	view →
SKCM	DFS	Tertile	All	0.928	0.725	.005	24	view →
COAD	DFS	Tertile	II,III,IV	0.269	0.663	.010	18	view →
KIRP	OS	Tertile	All	0.806	0.940	.006	15	view →
SARC	OS	Tertile	All	0.228	0.607	.018	9	view →
READ	DFS	Tertile	IV	0.274	0.690	.012	9	view →
BLCA	DFS	Tertile	II,III,IV	0.501	0.318	.048	6	view →
DLBC	OS	Quartile	II,III,IV	0.725	1.000	.016	3	view →

Pink = unfavorable, green = favorable. Showing the 8 strongest of 8 lineages.

RPL37P25–ACC (DFS)

Open the ACC breakdown →